Oncology Institute Stock Performance

TOI Stock  USD 2.61  0.16  6.53%   
The company holds a Beta of 1.87, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncology Institute will likely underperform. At this point, Oncology Institute has a negative expected return of -0.22%. Please make sure to check Oncology Institute's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Oncology Institute performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Oncology Institute has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more

Actual Historical Performance (%)

One Day Return
6.53
Five Day Return
(4.40)
Year To Date Return
(28.88)
Ten Year Return
(73.09)
All Time Return
(73.09)
1
The Oncology Institute Q3 2025 Earnings Call
11/13/2025
2
Acquisition by Robert Carter of 195 shares of Oncology Institute subject to Rule 16b-3
11/17/2025
3
A Mysterious Stock Has Rallied Over 950 percent This Year. Heres 1 Key Reason Why Investors Are Turning Bullish
11/21/2025
4
Acquisition by Kaushal Mohit of 40123 shares of Oncology Institute subject to Rule 16b-3
11/24/2025
5
Oncology Institute Projects Strong 2025 Revenue Growth - MSN
11/26/2025
6
The Oncology Institute Announces Resignation of Board Member Gabe Ling
12/01/2025
7
Disposition of 13333 shares by Hively Brad of Oncology Institute at 3.7719 subject to Rule 16b-3
12/15/2025
8
The Oncology Institute Making Progress - Seeking Alpha
12/18/2025
9
Disposition of 247 shares by Robert Carter of Oncology Institute at 3.56 subject to Rule 16b-3
01/02/2026
10
The Oncology Institute Announces Addition of Board Member Mark Stolper
01/05/2026
11
Assessing Oncology Institute Valuation After Mark Stolper Joins The Board
01/09/2026
Begin Period Cash Flow33.5 M
Total Cashflows From Investing Activities46.2 M

Oncology Institute Relative Risk vs. Return Landscape

If you would invest  331.00  in Oncology Institute on November 10, 2025 and sell it today you would lose (70.00) from holding Oncology Institute or give up 21.15% of portfolio value over 90 days. Oncology Institute is generating negative expected returns assuming volatility of 5.9605% on return distribution over 90 days investment horizon. In other words, 53% of stocks are less volatile than Oncology, and above 99% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon Oncology Institute is expected to under-perform the market. In addition to that, the company is 7.34 times more volatile than its market benchmark. It trades about -0.04 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

Oncology Institute Target Price Odds to finish over Current Price

The tendency of Oncology Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.61 90 days 2.61 
roughly 97.0
Based on a normal probability distribution, the odds of Oncology Institute to move above the current price in 90 days from now is roughly 97.0 (This Oncology Institute probability density function shows the probability of Oncology Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.87 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Oncology Institute will likely underperform. Additionally Oncology Institute has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Oncology Institute Price Density   
       Price  

Predictive Modules for Oncology Institute

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oncology Institute. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.132.668.61
Details
Intrinsic
Valuation
LowRealHigh
0.183.699.64
Details
Naive
Forecast
LowNextHigh
0.052.638.57
Details
1 Analysts
Consensus
LowTargetHigh
6.377.007.77
Details

Oncology Institute Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Oncology Institute is not an exception. The market had few large corrections towards the Oncology Institute's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oncology Institute, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oncology Institute within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.81
β
Beta against Dow Jones1.87
σ
Overall volatility
0.44
Ir
Information ratio -0.12

Oncology Institute Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncology Institute for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncology Institute can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Oncology Institute generated a negative expected return over the last 90 days
Oncology Institute has high historical volatility and very poor performance
Oncology Institute has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 393.41 M. Reported Net Loss for the year was (53.01 M) with profit before taxes, overhead, and interest of 63.75 M.
Oncology Institute has about 64.21 M in cash with (26.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89.

Oncology Institute Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncology Stock often depends not only on the future outlook of the current and potential Oncology Institute's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncology Institute's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding75 M
Cash And Short Term Investments49.7 M

Oncology Institute Fundamentals Growth

Oncology Stock prices reflect investors' perceptions of the future prospects and financial health of Oncology Institute, and Oncology Institute fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncology Stock performance.

About Oncology Institute Performance

By evaluating Oncology Institute's fundamental ratios, stakeholders can gain valuable insights into Oncology Institute's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncology Institute has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncology Institute has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 9.72  11.05 
Return On Tangible Assets(0.49)(0.52)
Return On Capital Employed(0.57)(0.60)
Return On Assets(0.43)(0.41)
Return On Equity(20.72)(19.68)

Things to note about Oncology Institute performance evaluation

Checking the ongoing alerts about Oncology Institute for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncology Institute help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Oncology Institute generated a negative expected return over the last 90 days
Oncology Institute has high historical volatility and very poor performance
Oncology Institute has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 393.41 M. Reported Net Loss for the year was (53.01 M) with profit before taxes, overhead, and interest of 63.75 M.
Oncology Institute has about 64.21 M in cash with (26.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89.
Evaluating Oncology Institute's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Oncology Institute's stock performance include:
  • Analyzing Oncology Institute's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncology Institute's stock is overvalued or undervalued compared to its peers.
  • Examining Oncology Institute's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Oncology Institute's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncology Institute's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Oncology Institute's stock. These opinions can provide insight into Oncology Institute's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Oncology Institute's stock performance is not an exact science, and many factors can impact Oncology Institute's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Oncology Stock analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stocks Directory
Find actively traded stocks across global markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities